

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number  
**WO 2007/039112 A1**

## (51) International Patent Classification:

A61K 31/167 (2006.01) C07D 213/30 (2006.01)  
 A61K 31/191 (2006.01) C07D 213/40 (2006.01)  
 A61K 31/341 (2006.01) C07D 213/75 (2006.01)  
 A61K 31/381 (2006.01) C07D 239/20 (2006.01)  
 A61K 31/4418 (2006.01) C07D 307/68 (2006.01)  
 A61K 31/4436 (2006.01) C07D 333/24 (2006.01)  
 A61K 31/505 (2006.01) C07D 409/04 (2006.01)  
 A61K 31/5377 (2006.01)

## (21) International Application Number:

PCT/EP2006/009153

## (22) International Filing Date:

20 September 2006 (20.09.2006)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

EP0520509.5 20 September 2005 (20.09.2005) EP

(71) Applicant (for all designated States except US):  
**REVOTAR BIOPHARMACEUTICALS AG** [DE/DE];  
 Neuendorfsstrasse 24a, 16761 Hennigsdorf (DE).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **AYDT, Ewald**  
 [DE/DE]; Lloyd-G. Wells-Strasse 20, 14163 Berlin (DE).  
**KRANICH, Remo** [DE/DE]; Hennigsdorfer Str. 141N,  
 13503 Berlin (DE).

(74) Agent: **ISENBRUCK, Günter**; Isenbruck, Bösl,  
 Hörschler, Wichmann, Huhn, Theodor-Heuss-Anlage 12,  
 68165 Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:


— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY



(I)



(II)



(III)

(57) Abstract: Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning -X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.

---

NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY

---

5

The present invention relates to compounds, compositions and methods for modulating the *in vitro* and *in vivo* processes mediated by cell adhesion molecules. The disclosed small molecules comprise 2,4,6-trihydroxy phenyl subunits and modulate cell adhesion molecule-mediated functions potently.

Cell-adhesion molecule-mediated functions are part of a complex cascade leading to the migration of circulating white blood cells (leukocytes) from the blood stream into the surrounding tissue (transmigration). Physiologically, leukocyte transmigration is of critical importance for homeostasis and immuno-surveillance of living beings including humans. Lymphocytes for example, are constitutively leaving the blood stream into lymphatic tissues in order to patrol for harmful antigens. Under pathological circumstances however, e.g. local or systemic inflammation and/or injury of the vascular system, this fundamental process is dys-regulated, at least in part, due to an increased surface expression of E- and P-selectin. Consequently, the excessive leukocyte transmigration leads to a pathological cellular infiltrate with subsequent tissue damage in several clinically relevant settings. Disease states such as Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS), Asthma bronchiale (asthma), Chronic Obstructive Pulmonary Disease (COPD), Psoriasis, Rheumatoid Arthritis, and Sepsis are all associated with tissue inflammation induced and perpetuated by pathologically activated leukocytes infiltrating the respective tissue. In addition, exaggerated leukocyte infiltration contributes to the pathogenesis of Ischemic-Reperfusion Injury (IRI) associated with organ transplantation, cardiopulmonary bypass or percutaneous transluminal angioplasty.

To transmigrate, leukocytes must bind to the wall of the vascular endothelium to diffuse through the cell wall of the capillary into the surrounding tissue. Therefore, leukocytes

have to roll onto and then adhere to the endothelial cell wall (initial rolling or “tethering”). This primary event in transmigration is mediated by the selectin family of cell-adhesion molecules. In addition to directly binding to the endothelium, leukocytes can adhere to other leukocytes, leukocyte-particles, platelets or platelet-derived particles that are already  
5 attached to the endothelium.

The selectin family of adhesion molecules is comprised of three structurally related calcium-dependent carbohydrate binding cell surface proteins, E-, P- and L-selectin. E-selectin is expressed only on inflamed endothelium, P-selectin is expressed on inflamed  
10 endothelium as well as on platelets and L-selectin is expressed on leukocytes. Selectins are composed of an amino terminal lectin domain, an epidermal growth factor (EGF)-like domain, a variable number of complement receptor-related repeats, a hydrophobic transmembrane domain and a C-terminal cytoplasmic domain. The binding interactions leading to the adhesion of the leukocytes are supposed to be mediated by contact of the  
15 lectin domain of the selectins and various carbohydrate ligands on the surface of the leukocytes. All three selectins can bind with low affinity to the carbohydrate sialyl Lewis<sup>x</sup> (sLe<sup>x</sup>), a glycosyl moiety present on the surface of most leukocytes. A structurally related glycosyl moiety, sialyl Lewis<sup>a</sup> (sLe<sup>a</sup>), is predominantly found on the surface of cancer cells [K. Okazaki et al., *J. Surg. Res.*, 1998, 78(1). 78-84; R. P. McEver et al., *Glycoconjugate*  
20 *Journal*, 1997, 14(5), 585-591]. In case of P-selectin, a distinct high affinity glycoprotein ligand has been described [R.P. McEver, R.D. Cummings, *J.Clin.Invest.*, 1997, 100, 485-492], the so-called P-selectin glycoprotein ligand-1 (PSGL-1), which contributes to a high affinity selectin binding by its sLe<sup>x</sup> moiety as well as by parts of its peptide components, in particular sulphated tyrosine residues [R.P. McEver, *Ernst Schering Res. Found.*  
25 *Workshop*, 2004, 44, 137-147]. PSGL-1 is one of the most important selectin ligands binding with highest affinity to P-selectin, but it also binds to E- and L-selectin [G. Constantin; *Drug News Perspect*; 2004; 17(9); 579-586]. It is a homodimeric sialomucin predominantly expressed on leukocytes.

30 In inflammatory diseases, dys-regulated transmigration is, at least in part, mediated due to an increased cell surface expression of E- and P-selectin. In contrast to their low basal expression, E- and P-selectin expression is upregulated during inflammation, leading to a

substantial recruitment of leukocytes into the inflamed tissue. Although selectin-mediated cell adhesion is required for fighting infection, there are various situations in which such cell adhesion is undesirable or excessive, resulting in severe tissue damage instead of repair. In the case of many acute as well as chronic inflammatory disorders [e.g., asthma,  
5 chronic obstructive pulmonary disease (COPD), psoriasis, etc.], an association between infiltration of activated leukocytes into the tissue simultaneously with a marked elevation of tissue expression of corresponding adhesion molecules, particularly E- and P-selectin, has been demonstrated [Muller et al., *J. Pathol.*, 2002, 198(2), 270-275; Di Stefano et al.,  
10 *Am. J. Respir. Crit. Care. Med.*, 1994, 149(3) 803-810; Terajima et al., *Arch. Dermatol. Res.*, 1998, 290, 246-252]

Leukocyte infiltration may also play a role in inflammatory symptoms in the course of transplant and graft rejection. Also the process of blood clotting is further promoted by leukocyte-leukocyte and leukocyte-platelet binding, which occurs because leukocytes  
15 possess both L-selectin and its corresponding ligand PSGL-1 and can thus interact with themselves via PSGL-1, and they can also bind to platelets which carry P-selectin.

Therefore, the modulation of selectin-mediated cell adhesion and other selectin mediated functions, e.g. leukocyte activation, offers a promising possibility to interfere with and stop  
20 the inflammation cascade at a very early step. Small molecule selectin antagonists should modulate all three selectins simultaneously as pan-selectin-antagonists to circumvent possible redundancies between the selectins [M. Sperandio et al., *Vascular Disease Prevention*, 2004, 1, 185-195].

Besides sLe<sup>x</sup>/sLe<sup>a</sup>, the natural, high affinity ligand PSGL-1 is another template structure for the design of small molecule selectin antagonists. As compared to sLe<sup>x</sup>/sLe<sup>a</sup>, PSGL-1 shows high affinity for all three selectins. To find and to detect novel small molecule drugs  
25 that compete with PSGL-1 and PSGL-1-like ligands for selectin binding is therefore a promising strategy to develop a novel class of effective pan-selectin antagonists for treating inflammatory disorders. Selectin antagonists may be designed using selectins as  
30 well as using a ligand like PSGL-1 as a template structure, since they are intended to

modulate the binding between selectins and PSGL-1 or other ligands with similar binding motifs.

Novel small molecule selectin antagonists could meet certain requirements to be drug-like and to have potential oral bioavailability. The term drug likeness is described in the literature [Lipinski; *Adv. Drug Dev. Rev.*, 1997, 23, 3-25]. Beside other molecular properties, passively transported molecules are supposed to have on average a relative molecular weight of less than 500 in order to be drug like. According to these rules it is common to define compounds with a relative molecular weight of less 500 or closely above that as small molecules. Compounds with relative molecular weights above 500 are unlikely to be orally bioavailable. Also the presence of highly polar carbohydrate moieties or a peptidic component is not in accordance with the concept of drug likeness [H. Ulbrich et al., *Trends Pharmacol. Sci.*, 2003, 24(12), 640-647; D. Slee et al., *J. Med. Chem.*, 2001, 44, 2094-2107]. The same accounts for the development of antibody-based drugs, because they are polypeptides and so oral administration is a problem. Moreover, the desired compounds must be stable during the passage through the gastrointestinal tract so that they can be ingested/absorbed latest by the cells of the small intestines. This is not the case for most glycosidic molecules and peptidic structures.

There have been various investigations to develop low-molecular weight compounds with a modulatory effect on selectin mediated processes. These compounds include disalicylates and disalicylate-based C-glycosides [WO 99/29706], benzyl amino sulfonic acids [WO 03/097658], diglycosylated 1,2-diols [WO 97/01569], substituted 5-membered heterocycles [WO 00/33836], mannopyranosyloxy-phenyl-benzoic acids [EP0758243 B1], piperazine based compounds [US6432957B1], gallic acid derivatives of peptides [WO 2004/018502], gallic acid [C. C. M. Appeldoorn et al., *Circulation* 2005, 111, 106-112; EP 1481669A1], and quinic acid derivatives [N. Kaila et al., *J. Med. Chem.* 2005, 48, 4346-4357]. However, none of these selectin-antagonizing compounds have successfully passed clinical trials up to date [S. J. Romano, *Treat. Respir Med* 2005, 4(2), 85-94; M. P. Schön, *Therapeutics and Clinical Risk Management*, 2005, 1(3), 201-208]. This is due to the fact, that many of these structures have been designed on the basis of the low potency template sLe<sup>x</sup>. Therefore, sLe<sup>x</sup>-mimicking structures are likely to show low potency. Other

compounds show specificity against different members of the selectin family, but antagonizing only selected selectins can be bypassed by other selectins [M. P. Schön, *Therapeutics and Clinical Risk Management*, 2005, 1(3), 201-208]. In addition, most of the compounds developed so far have high molecular weights and often bear carbohydrates and/or peptides making them prone to degradation and modification by peptidases and/or glycosidases. Carbohydrate-bearing structures have further disadvantages such as high degree of chirality, anomericity, and low probability of transport through lipid bilayers. Similar disadvantages are known for peptide-bearing compounds. Some other compounds developed for antagonizing selectin mediated processes contain pyrogallol- and catechol-substructures. These motifs are prone to oxidation processes [Kumamoto M. et al., *Biosci. Biotechnol. Biochem.*, 2001, 65(1), 126-132] making the pharmaceutical development of these compounds difficult. In addition, compounds with pyrogallol substructures, such as gallic acid, are known to be cytotoxic [E. Sergediene et al., *FEBS Letters*, 1999, 462, 392-396] and induce apoptosis [K. Satoh et al., *Anticancer Research*, 1997, 17, 2487-2490; N. Sakaguchi et al., *Biochemical Pharmacology*, 1998, 55, 1973-1981].

The leading compound in the field of selectin antagonists is bimosiamose [S. J. Romano, *Treat. Respir Med* 2005, 4(2), 85-94]. Presently bimosiamose [D. Bock et al., *New Drugs*, 2003, D04, 28, p.28; EP 0 840 606 B1] is the most advanced compound in clinical studies. Recent investigations support the hypothesis that bimosiamose can be considered as PSGL-1 mimetic [E. Aydt, G. Wolff, *Pathobiology*; 2002-2003; 70; 297-301]. This distinguishes bimosiamose from other selectin antagonists. It is, however, a high molecular weight compound with carbohydrate structures. The pan-selectin antagonist bimosiamose seems to lack oral bioavailability. Some observations indicate that bimosiamose shows good affinity for P-selectin and a moderate affinity for E- and L-selectin.


There is a strong medical need for novel highly potent pan-selectin antagonists which modulate selectin-mediated function, e.g. of selectin-dependent cell adhesion, and for the development of methods employing such compounds to modulate conditions associated with selectin-ligand interaction. Most of the available anti-inflammatory pharmaceutical therapies, which are available on the market, comprise mostly corticosteroids or NSAIDs (non steroidal anti-inflammatory drugs) having several serious drawbacks/side effects, and target different steps of the inflammatory cascade. Unlike this, modulating the selectin

function is a therapeutic concept intervening the inflammation cascade at a very early stage. Almost all promising selectin antagonists so far failed to become marketed drugs, mostly because of low potency and /or high molecular weight that causes problems in their absorption-distribution-metabolism-excretion (ADME) behaviour and thus in oral  
5 bioavailability required for the treatment of most inflammatory disorders like rheumatoid arthritis, septic shock, atherosclerosis, reperfusion injury and many others.

Object of the invention is to provide novel small molecules, especially non-glycosylated/non-glycosidic and non-peptidic compounds, which are able to potently  
10 antagonize selectin-mediated processes and which have less negative side effects during their application than prior art compounds.

Unlike most of the sLe<sup>x</sup>-mimicking compounds developed in this field, the inventive compounds are not prone to glycosidases or peptidases. Most of the selectin antagonists  
15 developed so far are structurally and biologically based on the properties of sLe<sup>x</sup> or sLe<sup>a</sup>. These resulting compounds showed, therefore, low biological activity like their template structures. This invention, however, provides novel potent small and drug like pan-selectin antagonists that have been invented on the basis of biological in vitro assays mimicking PSGL-1 and PSGL-1-like ligands or any ligands bearing sLe<sup>x</sup> or sLe<sup>a</sup> and tyrosinesulfate  
20 motifs [N. V. Bovin; *Biochem Soc Symp.*; 2002;(69):143-60. N. V. Bovin; *Glycoconj. J.*; 1998; 15(5); 431-46. T.V. Pochechueva et al.; *Bioorg Med Chem Lett.*; 2003;13(10);1709-12. G. Weitz-Schmidt et al.; *Anal. Biochem.*;1996; 238; 184-190].


The present invention provides pharmaceutical compositions comprising at least one  
25 compound having the general structure of formula (I) and a pharmaceutically acceptable carrier which is useful in medicine.



wherein the symbols and substituents have the following meaning:


-X- =

(a)




5 with  $m = 0, 1$ ;  $n =$  an integer from 1 to 3

(b)




10 wherein "ring" is



and with R<sup>1</sup> being H, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, CH<sub>3</sub>, NH<sub>2</sub>, NHalkyl, NHaryl, NHacyl and  $k = 0, 1$

15 (c)



T being O, S or [H,H];  $p = 0, 1, 2$ ,




(d)




the double bond is either *E*- or *Z*-configured

(e)




(f)



with -E- being  $-(CH_2)_qNH-$  and  $q = 0, 1, 2, 3$

-Y =

(a)



with  $s$  being 0 or 1,

$R^2$  being  $\text{CO}_2\text{H}$ ,  $\text{CO}_2\text{Alkyl}$ ,  $\text{CO}_2\text{Aryl}$ ,  $\text{CO}_2\text{NH}_2$ ,  $\text{CO}_2\text{Aralkyl}$ ,  $\text{SO}_3\text{H}$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{PO}(\text{OH})_2$ , 1-H-tetrazolyl-,  $\text{CHO}$ ,  $\text{COCH}_3$ ,  $\text{CH}_2\text{OH}$ ,  $\text{NH}_2$ ,  $\text{NHAlkyl}$ ,  $\text{N(Alkyl)Alkyl'}$ ,  $\text{OCH}_3$ ,  $\text{CH}_2\text{OCH}_3$ ,  $\text{SH}$ ,  $\text{F}$ ,  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$ ,  $\text{CH}_3$ ,  $\text{CH}_2\text{CH}_3$ ,  $\text{CN}$ ,  $\text{CF}_3$

$R^3$  independently from  $R^2$  being  $\text{H}$ ,  $\text{CH}_3$ ,  $\text{CH}_2\text{CH}_3$ ,  $\text{CF}_3$ ,  $\text{F}$ ,  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$ ,  $\text{CN}$ ,  $\text{NO}_2$  and


5  $R^4$  independently from  $R^2$  and  $R^3$  being  $\text{H}$ ,  $\text{CH}_3$ ,  $\text{CH}_2\text{CH}_3$ ,  $\text{CF}_3$ ,  $\text{F}$ ,  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$ ,  $\text{CN}$ ,  $\text{NO}_2$ ,  $R^2$

$R^5$  being  $\text{H}$ ,  $\text{NO}_2$ ,  $\text{CF}_3$ ,  $\text{F}$ ,  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$ ,  $\text{CN}$ ,  $\text{CH}_3$ ,  $\text{OCH}_3$ ,  $\text{SH}$ ,  $\text{NH}_2$

and  $-\text{W}- = -(\text{CH}_2)_v-$ , *cis*- $\text{CH}=\text{CH}-$  or *trans*- $\text{CH}=\text{CH}-$ , and  $v$  being 0,1,2;


in case that  $-\text{W}-$  is *cis*- $\text{CH}=\text{CH}-$  or *trans*- $\text{CH}=\text{CH}-$ ,  $R^2$  must not be  $\text{NH}_2$  or  $\text{SH}$ ;

10 (b)




$R^6$  independently from  $R^2$  being  $\text{H}$ ,  $\text{F}$ ,  $\text{Cl}$ ,  $\text{Me}$ , *tert*-Bu,  $\text{CN}$ ,  $\text{NH}_2$

(c)




15

(d)




(e)



20


with t being 0,1,2

(f)




5

(g)



-Z =


(i)



10

$R^7$  independently from  $R^2$  being H, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, CH<sub>3</sub>, OCH<sub>3</sub>, SH, NH<sub>2</sub>,


(ii)



15

$R^8$  independently from  $R^2$  being H, F, Cl, Me, tert-Bu, CN, NH<sub>2</sub>

(iii)




(iv)




5 with K = NH, NMe, O, S

(v)



(vi)



10

(vii)


-W-R<sup>2</sup>

15

or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formula (I).

In a further embodiment, the invention relates to pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine,


- 12 -



wherein the symbols and substituents have the following meaning


-X- =

(a)




with  $m = 0, 1$ ;  $n =$  an integer from 1 to 3

(b)




wherein "ring" is



and with  $R^1$  being H,  $NO_2$ ,  $CF_3$ , F, Cl, Br, I, CN,  $CH_3$ ,  $NH_2$ ,  $NHalkyl$ ,  $NHAryl$ ,  $NHAcyl$  and  $k = 0, 1$

(c)




T being O, S or [H,H]; p = 0,1,2,

5

-Y =

(a)



with s being 0 or 1,

10


R<sup>2</sup> being CO<sub>2</sub>H, CO<sub>2</sub>Alkyl, CO<sub>2</sub>Aryl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>Aralkyl, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, PO(OH)<sub>2</sub>, 1-H-tetrazolyl-, CHO, COCH<sub>3</sub>, CH<sub>2</sub>OH, NH<sub>2</sub>, NHAlkyl, N(Alkyl)Alkyl', OCH<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub>, SH, F, Cl, Br, I, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CN, CF<sub>3</sub>

R<sup>3</sup> independently from R<sup>2</sup> being H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, NO<sub>2</sub> andR<sup>4</sup> independently from R<sup>2</sup> and R<sup>3</sup> being H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, NO<sub>2</sub>, R<sup>2</sup>

15

R<sup>5</sup> being H, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, CH<sub>3</sub>, OCH<sub>3</sub>, SH, NH<sub>2</sub>and -W- = -(CH<sub>2</sub>)<sub>v</sub>, *cis*-CH=CH- or *trans*-CH=CH-, and v being 0,1,2;in case that -W- is *cis*-CH=CH- or *trans*-CH=CH-, R<sup>2</sup> must not be NH<sub>2</sub> or SH;


(b)




20

R<sup>6</sup> independently from R<sup>2</sup> being H, F, Cl, Me, tert-Bu, CN, NH<sub>2</sub>

(c)



(e)




5

with t being 0,1,2

-Z =

(i)



10

$R^7$  independently from  $R^2$  being H,  $\text{NO}_2$ ,  $\text{CF}_3$ , F, Cl, Br, I, CN,  $\text{CH}_3$ ,  $\text{OCH}_3$ , SH,  $\text{NH}_2$ ,


(iv)



15


with K = NH, NMe, O, S

(v)





or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formula (I).

- 5 Preferred pharmaceutical compositions comprise compounds of formula (II)




wherein -Y is like defined above and wherein -X'- is X (a), X (b), X (c), and X (d) like defined above. Preferred are compounds of formula (II) wherein -X'- is X(a) or X(b).

Further preferred pharmaceutical compositions comprise compounds of formulas (A) or (B)




wherein -X'- and -Y are like defined above and wherein -X''- is





and wherein -Y' is






wherein all indices, symbols and substituents are like defined above.

- 5 In a further embodiment, the invention relates to pharmaceutical compositions, wherein the compounds are defined by formulas (A) or (B)




10

wherein  $-X'$ - and  $-Y$  are as defined as above and wherein  $-X''-$  is




and wherein -Y' is



wherein all other indices, symbols and substituents are as defined above.

5


Particularly preferred pharmaceutical compositions comprise compounds of formula (C)



wherein -X''- and -Y' are like defined above.


10

Very particularly preferred pharmaceutical compositions comprise compounds of formula (D)



wherein -X''- is like defined above and -Y'' is


15



with  $R^9$  being  $\text{CO}_2\text{H}$ ,  $\text{CO}_2\text{alkyl}$ ,  $\text{CO}_2\text{aryl}$ ,  $\text{CO}_2\text{NH}_2$ ,  $\text{CO}_2\text{aralkyl}$ ,  $\text{CH}_2\text{SO}_3\text{H}$ ,  $\text{CH}_2\text{SO}_2\text{NH}_2$ ,  $\text{CH}_2\text{PO}(\text{OH})_2$ , 1-H-tetrazolyl,  $\text{CHO}$ ,  $\text{COCH}_3$ ,  $\text{CH}_2\text{OH}$ ,  $\text{CH}_2\text{NH}_2$ ,  $\text{CH}_2\text{NHalkyl}$ ,  $\text{CH}_2\text{N(alkyl)alkyl'}$ ,  $\text{CH}_2\text{OCH}_3$ ,  $\text{CH}_2\text{SH}$ .


5

In a further embodiment, the invention relates to pharmaceutical compositions, wherein the compounds are defined by formula (D)



10

wherein  $\text{-X''-}$  is as defined as above and  $\text{-Y''}$  is



with  $R^9$  being  $\text{CO}_2\text{H}$ ,  $\text{CO}_2\text{alkyl}$ ,  $\text{CO}_2\text{aryl}$ ,  $\text{CO}_2\text{NH}_2$ ,  $\text{CO}_2\text{aralkyl}$ ,  $\text{CH}_2\text{SO}_3\text{H}$ ,  $\text{CH}_2\text{SO}_2\text{NH}_2$ ,  $\text{CH}_2\text{PO}(\text{OH})_2$ , 1-H-tetrazolyl,  $\text{CHO}$ ,  $\text{COCH}_3$ ,  $\text{CH}_2\text{OH}$ ,  $\text{CH}_2\text{NH}_2$ ,  $\text{CH}_2\text{NHalkyl}$ ,  $\text{CH}_2\text{N(alkyl)alkyl'}$ ,  $\text{CH}_2\text{OCH}_3$ ,  $\text{CH}_2\text{SH}$ ,

15

wherein all other indices, symbols and substituents are as defined above.

These chemical compounds (C) and (D) are also new compounds for themselves.

All compounds as described before present the ability of modulating cell adhesion and modulate selectin- as well as PSGL-1-like mediated binding. The compounds have the ability to modulate the interaction of selectins with sLe<sup>x</sup>/sLe<sup>a</sup> and also the interaction  
5 between selectins and tyrosinesulfate residues. Therefore they are useful for the treatment of acute and chronic inflammatory disorders, as well as other medical conditions where selectin mediated processes play a role.

The term "pharmaceutical" includes also diagnostic applications.

- 10 The term "pharmaceutical" includes also prophylactic applications in order to prevent medical conditions where selectin mediated processes play a role.

The term "pharmaceutical" includes also applications, where compounds of the present invention may be used as vehicles for drug targeting of diagnostics or therapeutics.

- 15 The invention provides pharmaceutical compositions comprising compounds of formula (I) and in a preferred variant of formula (II).

In a further preferred variant the invention provides pharmaceutical compositions comprising at least one compound of formula (A) or (B).

- In a particularly preferred variant the invention provides pharmaceutical compositions  
20 comprising at least one compound of formula (C).

In a very particularly preferred variant the invention provides pharmaceutical compositions comprising at least one compound of formula (D).

- The present invention further provides a method of modulating the binding of P-selectin, L-selectin or E-selectin to sLe<sup>x</sup> or sLe<sup>a</sup> and tyrosinesulfate residues comprising the step of  
25 administering to a patient an effective amount of at least one compound having the structure of formula (I) to modulate the binding of P-, E- or L-selectin to sLe<sup>x</sup> or sLe<sup>a</sup> and

tyrosinesulfate. It has been found that compounds having the formula (I) shown above act to modulate E-, P- or L-selectin binding.

As used herein the terms "alkyl" shall mean a monovalent straight chain or branched chain group of 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl and the like. "Alkyl" is independently from each other and can be different or identical.

The term "aryl" shall mean carbocyclic and heterocyclic aromatic groups including, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, fluorenyl, (1,2)-dihydronaphthyl, indenyl, indanyl, thienyl, benzothienyl, thienopyridyl and the like.

The term "aralkyl" (also called arylalkyl) shall mean an aryl group appended to an alkyl group including, but not limited to, benzyl, 1-naphthylmethyl, 2-naphthylmethyl, fluorobenzyl, chlorobenzyl, bromobenzyl, iodobenzyl, alkoxybenzyl (wherein "alkoxy" means methoxy, ethoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy and the like), hydroxybenzyl, aminobenzyl, nitrobenzyl, guanidinobenzyl, fluorenylmethyl, phenylmethyl(benzyl), 1-phenylethyl, 2-phenylethyl, 1-naphthylethyl and the like.

The term "acyl" shall mean -(CHO) or -(C=O)-alkyl or -(C=O)-aryl or -(C=O)-aralkyl including, but not limited to, formyl, acetyl, n-propionyl, isopropionyl, n-butyryl, isobutyryl, pivaloyl, benzoyl, 4-nitrobenzoyl and the like.

The term "pharmaceutically acceptable salts, esters, amides and prodrugs" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with tissues of patients without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds or

by separately reacting the purified compounds in its free form with a suitable inorganic or organic acid or base and isolating the salt thus formed. Representative salts of the compounds of the present invention include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

Examples of the pharmaceutically acceptable, non-toxic esters of the compounds of this invention include C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C<sub>5</sub>, C<sub>6</sub> and C<sub>7</sub> cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> alkyl ester are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.

Examples of pharmaceutically acceptable, non-toxic amides of compounds of this invention include amides derived from ammonia, primary C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> alkyl amines and secondary C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> dialkyl amines wherein the alkyl groups are straight or branched chains. In the case of secondary amines the amine may also be in the form of a 5 or 6 membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C<sub>1</sub>, C<sub>2</sub> and C<sub>3</sub> alkyl primary amides and C<sub>1</sub> to C<sub>2</sub> dialkyl secondary amides are preferred. Amides of the compounds of the present invention may be prepared according to conventional methods.

The term “prodrug” refers to one or more compounds that are rapidly transformed *in vitro* and from a non-active to active state *in vivo* to yield the parent compound of the above formula (I), for example by hydrolysis in blood or *in vivo* metabolism.

- 5 It is also contemplated that pharmaceutically active compositions may contain a compound of the present invention or other compounds that modulate or compete with E-selectin or P-selectin or L-selectin binding.

Pharmaceutically active compositions of the present invention comprise a pharmaceutically acceptable carrier and a compound of formula (I), whereby a  
10 pharmaceutically acceptable carrier can also be a medically appropriate nano-particle, dendrimer, liposome, microbubble or polyethylene glycol (PEG). The pharmaceutical compositions of the present invention may include one or more of the compounds having the above structure (I) formulated together with one or more, physiologically acceptable carriers, adjuvants or vehicles, which are collectively referred to herein as carriers, for  
15 parenteral injection, for oral administration in solid or liquid form, for rectal or topical administration and the like.

The compositions can be administered to humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, intradermally or subcutaneously),  
20 intracisternally, intravaginally, interperitoneally, locally (powders, ointments or drops), or as a buccal or by inhalation (nebulized, or as nasal sprays).

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, stabilizers, antioxidants, preservatives (e.g.  
25 ascorbic acid, sodium sulfite, sodium hydrogen sulfite, benzyl alcohol, EDTA), dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solution or dispersion. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyol, (propylene glycol, polyethylene glycol, glycerol and the like), suitable mixtures thereof, vegetable oils (such  
30 as olive or canola oil) and injectable organic esters such as ethyl oleate. Proper fluidity can

be maintained, for examples, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

5 These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Prevention of the actions of microorganisms can be ensured by various antibacterial and antifungal agents, for examples, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for examples sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for examples  
10 aluminium monostearate and gelatin.

If desired, and for more effective distribution, the compounds can be incorporated into slow or timed release or targeted delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-  
15 retaining filter, or by incorporating sterilizing agents in the form of sterile water, or some other sterile injectable medium immediately before use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound or a prodrug is admixed with at  
20 least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (i) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (ii) binders, as for example, carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, sucrose and acacia, (iii) humectants, as for example, glycerol, (iv) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or  
25 tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (v) solution retarders, as for examples, paraffin, (vi) absorption accelerators, as for example, quaternary ammonium compounds, (vii) wetting agents, as for examples, cetyl alcohol and glycerol monostearate, (viii) adsorbents, as for example, kaolin and bentonite, and (ix) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium



lauryl sulfate and mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

5 Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatine capsules using excipients as lactose or milk sugars as well as high molecular polyethylene glycols and the like. Solid dosage forms such as tablets, dragées, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such compositions that they release the active compound or compounds in a certain part of the  
10 intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

15 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,  
20 propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, canola oil, castor oil and sesame seed oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances, and the like. Besides such inert diluents, the compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents,  
25 sweetening, flavouring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, tragacanth or  
30 mixtures of these substances and the like.

Compositions for rectal administrations are preferably suppositories, which can be prepared by mixing the compounds of the present invention with suitable nonirritating excipients or carriers such as cacao butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore melt in the rectal or vaginal cavity and release the active component. Dosage forms for topical administration of a compound of this invention include ointments, powder, sprays and inhalants.

The active component is admixed under sterile conditions with a physiologically acceptable carrier and any needed preservatives, buffers or propellants as may be required. Ophthalmic formulations, eye ointments, suspensions, powder and solutions are also contemplated as being within the scope of this invention.

The compounds of the present invention can also be incorporated into or connected to liposomes or administrated in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable metabolized lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the selectin binding antagonists of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are well known in the art.

Non-parenteral dosage forms may also contain a bioavailability enhancing agent (e.g. enzyme modulateors, antioxidants) appropriate for the protection of the compounds against degradation. Actual dosage levels of active ingredient in the composition of the present invention may be varied so as to obtain an amount of active ingredient that is effective to obtain the desired therapeutic response for a particular composition and method of administration. The selected dosage level, therefore, depends on the desired therapeutic effect, on the route of administration, on the desired duration of treatment and other factors. The total daily dosage of the compounds on this invention administered to a host in

single or divided doses may be in the range up to 50 mg per kilogram of body weight. Dosage unit compositions may contain such submultiples thereof as may be used to make up the daily dosage. It will be understood, however, that the specific dose level for any particular patient, whether human or other animal, will depend upon a variety of factors  
5 including the body weight, general health, sex diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

In particular, the compounds of the present invention may be used to treat a variety of  
10 diseases relating to inflammation and cell-cell recognition and adhesion. For example, the compounds of the present invention may be administered to a patient to treat Chronic Obstructive Pulmonary Disease (COPD), acute lung injury (ALI), cardiopulmonary bypass, acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases such as psoriasis, atopic dermatitis, and rheumatoid  
15 arthritis, and reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, and organ transplants, traumatic shock, multi-organ failure, autoimmune diseases like multiple sclerosis, percutaneous transluminal angioplasty, asthma and inflammatory bowel disease. In each case, an effective amount of the compounds of the present invention is administered either alone or as part of a pharmaceutically active composition to a patient in  
20 need of such treatment. It is also recognized that a combination of the compounds may be administered to a patient in need of such administration. The compounds of the present invention may also be administered to treat other diseases that are associated with cell-cell adhesion. As the present compounds modulate the binding of E-selectin or P-selectin or L-selectin, any disease that is related to this interaction may potentially be treated by the  
25 modulation of this binding interaction.

In addition to being found on some white blood cells, sLe<sup>a</sup> is found on various cancer cells, including lung and colon cancer cells. It has been suggested that cell adhesion involving sLe<sup>a</sup> may be involved in the metastasis of certain cancers and antagonists of sLe<sup>a</sup> binding  
30 might be useful in treatment of some forms of cancer.

The use of the active ingredients according to the invention or of cosmetic or topical dermatological compositions with an effective content of active ingredient according to the invention surprisingly enables effective treatment, but also prophylaxis of skin ageing caused by extrinsic and intrinsic factors.

5

The invention particularly relates to the use of a compound of formula (I) or a stereoisomeric form thereof for the preparation of a cosmetic or dermatological composition.

- 10 The amount used of the active compound or a stereoisomeric form thereof corresponds to the amount required to obtain the desired result using the cosmetic or dermatological compositions. One skilled in this art is capable of evaluating this effective amount, which depends on the derivative used, the individual on whom it is applied, and the time of this application. To provide an order of magnitude, in the cosmetic or dermatological
- 15 compositions according to the invention, the compound of formula (I) or a stereoisomeric form thereof may be administered in an amount representing from 0.001% to 40% by weight, preferentially 0.005% to 30% by weight and more preferentially from 0.01% to 20% by weight.
- 20 A further aspect covers cosmetic compositions comprising a compound of formula (I) or a stereoisomeric form thereof and at least one cosmetically tolerable component, e.g. a cosmetically tolerable component for skin applications.

25

The amounts of the various components of the physiological medium of the cosmetic composition according to the invention are those generally included in the fields under

consideration. When the cosmetic composition is an emulsion, the proportion of the fatty phase may range from 2% to 80% by weight and preferably from 5% to 50% by weight relative to the total weight of the cosmetic composition.

5 Thus, the cosmetic composition should contain a non-toxic physiologically acceptable medium that can be applied to human skin. For a topical application to the skin, the cosmetic composition may be in the form of a solution, a suspension, an emulsion or a dispersion of more or less fluid consistency and especially liquid or semi-liquid consistency, obtained by dispersing a fatty phase in an aqueous phase (O/W) or,  
10 conversely, (W/O), or alternatively a gel. A cosmetic composition in the form of a mousse or in the form of a spray or an aerosol then comprising a pressurized propellant may also be provided. Also the compositions may be in the form of a haircare lotion, a shampoo or hair conditioner, a liquid or solid soap, a treating mask, or a foaming cream or gel for cleansing the hair. They may also be in the form of hair dye or hair mascara.

15

The cosmetic compositions of the invention may also comprise one or more other ingredients usually employed in the fields under consideration, selected from among formulation additives, for instance aqueous-phase or oily-phase thickeners or gelling agents, dyestuffs that are soluble in the medium of the cosmetic composition, solid  
20 particles such as mineral or organic fillers or pigments in the form of microparticles or nanoparticles, preservatives, fragrances, hydrotopes or electrolytes, neutralizers (acidifying or basifying agents), propellants, anionic, cationic or amphoteric surfactants, polymers, in particular water-soluble or water-dispersible anionic, nonionic, cationic or amphoteric film-forming polymers, mineral or organic salts, chelating agents; mixtures thereof.

25

The cosmetic compositions may be used to inhibit the micro-inflammatory cycle. Thus, the present invention also relates to cosmetic compositions comprising a compound of formula (I) or a stereoisomeric form thereof that is used for the cosmetic treatment or cosmetic prophylaxis of micro-inflammatory conditions.

30

Cosmetic compositions comprising a compound of formula (I) or a stereoisomeric form thereof that is used for the cosmetic treatment or cosmetic prophylaxis of skin ageing caused by intrinsic factors are also subject of the present invention. Intrinsic factors responsible for skin ageing are genetically programmed determinants including age,  
5 hormonal status, and psychological factors.

Beside cosmetically inactive ingredients the cosmetic compositions of the present invention may also comprise one or more cosmetically active ingredients with beneficial action on the skin. Thus, the present invention relates to cosmetic compositions comprising  
10 a compound of formula (I) or a stereoisomeric form thereof and at least one further cosmetically active ingredient, e.g. an UV-blocker or proteins.

Dermatological compositions comprising a compound of formula (I) or a stereoisomeric form thereof and at least one dermatologically tolerable component, e.g. a dermatologically  
15 tolerable component for skin applications, are also subject of the invention.

Dermatologically tolerable components that can be used for the dermatological compositions described here are identical to the cosmetically tolerable components as defined in this invention.

20 A further embodiment of this invention are dermatological compositions comprising a compound of formula (I) or a stereoisomeric form thereof that is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of micro-inflammatory conditions.

25 In particular the invention covers dermatological compositions comprising a compound of formula (I) or a stereoisomeric form thereof that is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of itching and skin ageing caused by extrinsic factors. Extrinsic factors include environmental factors in general; more particularly photo-ageing due to exposure to the sun, to light or to any other radiation,

atmospheric pollution, wounds, infections, traumatisms, anoxia, cigarette smoke, hormonal status as response to external factors, neuropeptides, electromagnetic fields, gravity, lifestyle (e.g. excessive consumption of alcohol), repetitive facial expressions, sleeping positions, and psychological stressors.

- 5 In addition to dermatologically inactive ingredients the dermatological compositions may also comprise dermatologically or pharmaceutically active ingredients. Thus, the present invention also relates to dermatological compositions comprising a compound of formula (I) or a stereoisomeric form thereof and at least one further dermatologically or pharmaceutically active ingredient. The dermatologically or pharmaceutically active ingredients that can be used  
10 for the dermatological compositions described herein are defined as the cosmetically active ingredients defined above. Dermatologically or pharmaceutically active ingredients can be identical to the cosmetically active ingredients as defined in this invention.

- Another subject of the present invention are dermatological compositions comprising a compound of formula (I) or a stereoisomeric form thereof and at least one further  
15 dermatologically or pharmaceutically active ingredient characterized in that is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of micro-inflammatory conditions.

- In particular, the present invention relates to dermatological compositions comprising a compound of formula (I) or a stereoisomeric form thereof and at least one further  
20 dermatologically or pharmaceutically active ingredient characterized in that it is used for the dermatological treatment, dermatological diagnosis or dermatological prophylaxis of itching and skin ageing caused by extrinsic factors.

- Ageing of the skin may also be caused by a combination of intrinsic and extrinsic factors. Therefore, the present invention also relates to dermatological compositions comprising a  
25 compound of formula (I) or a stereoisomeric form thereof and at least one further pharmaceutically or cosmetically active ingredient characterized in that it is used for the cosmetic and dermatological treatment and cosmetic and dermatological prophylaxis of skin ageing caused by a combination of intrinsic and extrinsic factors.


Another embodiment of this invention is a process for the preparation of a cosmetic composition by mixing a compound of formula (I) or a stereoisomeric form thereof, at least one cosmetically tolerable component and eventually further cosmetically active ingredients.

5 In particular, a process for the preparation of a cosmetic composition by mixing a compound of formula (I) or a stereoisomeric form thereof, at least one cosmetically tolerable component and eventually further cosmetically active ingredients, wherein the composition includes from 0.01% to 20% by weight of compound of formula (I) or a stereoisomeric form thereof, based on the total weight of the composition is subject of this invention.


10 A further aspect deals with a process for the preparation of a dermatological composition by mixing a compound of formula (I) or a stereoisomeric form thereof, at least one dermatologically tolerable component and eventually further pharmaceutically active ingredients.



Many of the compounds of the present invention may be synthesized according to the following general synthetic schemes.


**SCHEME 1**

- 5 In SCHEME 1 an aniline of type (1) is reacted under inert atmosphere conditions with N'-  
 (3-dimethylaminopropyl)-N-ethyl carbodiimide (EDC), triethylamine, 4-dimethylamino-  
 pyridine (DMAP) and a carboxylic acid of type (2) in dichloromethane to give an amide of  
 type (3). Amide of type (3) is further reacted with boron tribromide in dichloromethane at  
 -78°C to obtain the corresponding 2,4,6-trihydroxyphenyl of type (4). The synthesis  
 10 sequence shown in SCHEME 1 leading to compounds like (4) is not only reduced to Y-H  
 building blocks like (1) but may be generally applied to all other Y-H type building blocks.

**SCHEME 2**

In SCHEME 2 a brominated aromatic or heteroaromatic ester of generell type (5) is reacted under inert conditions with 2,4,6-trimethoxyphenylboronic acid (6) under Suzuki-type basic conditions ( $\text{Pd(PPh}_3)_4$  and aqueous sodium bicarbonate in dimethoxyethane) to a biaryl of type (7) which is further hydrolyzed with aqueous lithium hydroxide in acetonitrile to give the corresponding carboxylic acid (8) which is converted to a building block of type (9) by reaction with oxalyl chloride in anhydrous dichloromethane.

SCHEME 3




In SCHEME 3 an acid chloride like (9) is reacted with an aniline of general type (10) under basic conditions (pyridine in dichloromethane) to form the corresponding anilide (11). Alternatively triethylamine may be used for this reaction step. Ester (11) is hydrolyzed with LiOH in MeCN or THF/MeOH to obtain a carboxylic acid like (12) which is further reacted with boron tribromide in dichloromethane at -78°C to obtain after following aqueous workup corresponding demethylated acids of type (13). The synthesis sequence shown in SCHEME 3 leading to compounds like (13) is not only reduced to Y-H building blocks like (10) but may be generally applied to all other Y-H type building blocks.

The present invention is furthermore illustrated by the following representative examples.

#### EXAMPLE 1

#### 3-[2-(2,4,6-Trihydroxy-phenyl)-acetyl-amino]-benzoic acid (18)

SCHEME 4



**Step 1:** (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve EDC hydrochloride (122mg, 0.64mmol) and triethylamine (89μL, 0.64mmol) in anhydrous dichloromethane (3.2mL) and stir for 5min at rt. Add 2-(2,4,6-Trimethoxyphenyl)-acetic acid (14) (101mg, 0.45mmol) and DMAP (8mg, 0.06mmol) and stir for 10min. Add ethyl ester (15) (70mg, 0.42mmol) and stir the reaction solution overnight at rt. Hydrolize the reaction solution with saturated aqu. NH<sub>4</sub>Cl followed by water, separate layers, extract aqu. layer with dichloromethane (3 times) and wash the combined organic layers with water and brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure. Purify crude product by preparative radial chromatography (silica gel 60PF, EtOAc/CyH 1+1) to obtain 3-[2-(2,4,6-Trimethoxy-phenyl)-acetylamino]-benzoic acid methyl ester (16) as a white solid (145mg, 95%). [K. C. Nicolaou; P. S. Baran; Y.-L. Zhong; K. Sugita; *J. Am. Chem. Soc.*; **2002**; 124; 10; 2212-2220]. <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 3.68 (s, 2 H); 3.83 (s, 3 H); 3.84 (s, 6 H); 3.87 (s, 3 H); 6.18 (s, 2 H); 7.33 (t, 1 H, *J* = 8.0Hz); 7.56 (br.s, 1 H); 7.69 (br.dd, 1 H, *J* = 7.8Hz); 7.78 (t, 1 H, *J* = 1.8Hz); 7.90 (dd, 1 H, *J*<sub>1</sub> = 8.1Hz, *J*<sub>2</sub> = 1.3Hz).

**Step 2:** Dissolve 3-[2-(2,4,6-Trimethoxy-phenyl)-acetylamino]-benzoic acid methyl ester (16) (140mg, 0.39mmol) in THF (25.0mL) at rt and add 1M aqu LiOH (2.0mL, 2.0mmol). Stir reaction mixture 40h at rt. Quench reaction mixture (cooling bath) with 2M aqu. HCl. Extract the mixture with EtOAc (3x), wash the combined organic layer with brine and dry with Na<sub>2</sub>SO<sub>4</sub> to obtain 3-[2-(2,4,6-Trimethoxy-phenyl)-acetylamino]-benzoic acid (17) (134mg, 99%) as a beige solid. <sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD): 3.71 (s, 2 H); 3.84 (s, 3 H); 3.85 (s, 6 H); 6.29 (s, 2 H); 7.43 (t, 1 H, *J* = 7.8Hz); 7.76 (d, 1 H, *J* = 7.8Hz); 7.83 (d, 1 H, *J* = 8.1Hz); 8.19 (br.s, 1 H).

**Step 3** (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve 3-[2-(2,4,6-Trimethoxy-phenyl)-acetylamino]-benzoic acid (17) (134mg, 0.39mmol) in anhydrous DCM (5.3mL), cool the solution to -78°C and add dropwise BBr<sub>3</sub> (240μL, 2.55mmol). Stir the reaction mixture for 30min at -78°C and after slowly warming up for additional 2h at rt. Add dropwise ice water, separate layers and extract aqu. layer with EtOAc (3 times). Wash combined organic layer with brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Purify the crude product by preparative RP HPLC (gradient, water/CH<sub>3</sub>CN 95:5 to 5:95) to obtain 3-[2-(2,4,6-Trihydroxy-phenyl)-acetylamino]-benzoic acid (18) (29mg, 22%) as a yellowish


solid.  $^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ): 3.69 (s, 2 H); 5.97 (s, 2 H); 7.43 (t, 1 H,  $J = 8.0\text{Hz}$ ); 7.76 (br.dd, 1 H,  $J_1 = 7.6\text{Hz}$ ); 7.84 (br.dd, 1 H,  $J_1 = 8.1\text{Hz}$ ); 8.17 (t, 1 H,  $J = 1.8\text{Hz}$ ).

## EXAMPLE 2

5

**2-Methyl-5-{4-[2-(2,4,6-trihydroxy-phenyl)-acetyl-amino]-phenyl}-furan-3-carboxylic acid (19)**

**SCHEME 5**



10

According to the procedure described in EXAMPLE 1 2-Methyl-5-{4-[2-(2,4,6-trihydroxy-phenyl)-acetyl-amino]-phenyl}-furan-3-carboxylic acid (19) is obtained as a beige solid.  $^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ): 2.66 (s, 3 H); 3.68 (s, 2 H); 5.97 (s, 2 H); 6.89 (s, 1 H); 7.60 (dd, 2 H,  $J_1 = 9.1\text{Hz}$ ,  $J_2 = 2.3\text{Hz}$ ); 7.64 (dd, 2 H,  $J_1 = 9.1\text{Hz}$ ,  $J_2 = 2.3\text{Hz}$ ).


15

20

In the following, the preparation of intermediates is described:

**[5-(2-Amino-phenyl)-thiophen-2-yl]-acetic acid methyl ester (44)**

**SCHEME 7**



5

**Step 1:** (The following reaction is carried out in an anhydrous  $\text{N}_2$  atmosphere.) Dissolve thiophene-2-yl-acetic acid methyl ester (42) (2.0 g, 12.8 mmol) in anhydrous chloroform (9.0 mL) and glacial acetic acid (9.0 mL), add *N*-bromosuccinimide (2.3 g, 13.0 mmol) in portions and stir the mixture for 3 d at rt. Add water to the reaction mixture, separate layers and extract the aqu. layer with dichloromethane. Wash combined organic layer several times with a 1 M aqu. NaOH and water and once with brine and dry it with  $\text{Na}_2\text{SO}_4$ . Purify the crude product by preparative radial chromatography (CyH/EtOAc 5+1] to obtain (5-bromo-thiophen-2-yl)-acetic acid methyl ester (43) as a yellow oil (2.46 g, 81%) which is used without any further purification.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ): 3.71 (s, 3 H); 3.75 (s, 2 H); 6.67 (d, 1 H,  $J = 3.8$  Hz); 6.88 (d, 1 H,  $J = 3.8$  Hz).


**Step 2:** (The following reaction is carried out in an  $\text{N}_2$  atmosphere.) Ethanol (3.7 mL), tetrakis-(triphenylphosphine)-palladium(0) (289 mg, 0.25 mmol) and  $\text{Na}_2\text{CO}_3$  decahydrate (4.0 g, 14.0 mmol) dissolved in water (5.2 mL) are subsequently added to a solution of 2-amino-benzeneboronic acid hydrochloride (910 mg, 5.25 mmol) in toluene (52 mL). Degas the reaction mixture carefully (5 times) and flush with  $\text{N}_2$  again. A solution of (5-bromo-thiophen-2-yl)-acetic acid methyl ester (43) (1.17 g, 5.0 mmol) in toluene (4.5 mL) is added. Degas the mixture again (5 times) and stir for 22 h at 100 °C. Partition the reaction solution between EtOAc and brine and extract the separated aqueous layer with EtOAc (3 times). Wash combined organic layer with water and brine and dry it with  $\text{Na}_2\text{SO}_4$ . Purify the crude product by preparative radial chromatography (CyH/EtOAc 5+1] to obtain [5-(2-

25

amino-phenyl)-thiophen-2-yl]-acetic acid methyl ester (44) as a brown oil (634 mg, 51%).  
<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.73 (s, 3 H); 3.83 (s, 2 H); 3.92-4.07 (br.s, 2 H); 6.74 (d, 1 H); 6.76 (td, 1 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.3 Hz); 6.92 (d, 1 H, *J* = 3.5 Hz); 7.02 (d, 1 H, *J* = 3.5 Hz); 7.11 (td, 1 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.5 Hz); 7.23 (dd, 14 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.5 Hz).

### 5-(2-Amino-phenyl)-thiophene-2-carboxylic acid methyl ester (47)

#### SCHEME 8




**Step 1:** LE23 Dissolve 5-Bromo-thiophene-2-carboxylic acid (45) (1.50g, 7.24mmol) in methanol (10mL) and add conc. sulfuric acid (0.39mL, 7.24mmol). Stir the reaction mixture for 20h at 75°C. Cool mixture to rt, remove solvent under reduced pressure and resolve the residue in EtOAc. Wash this organic layer 3 times with 5% aqu. Na<sub>2</sub>CO<sub>3</sub> and extract the combined aqueous layer with EtOAc. Wash the combined organic layers with brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain ester (46) as a white solid (1.48g, 92%).  
<sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 3.85 (s, 3 H); 7.05 (d, 1 H, *J* = 4.0 Hz); 7.53 (d, 1 H, *J* = 4.0 Hz).

**Step 2:** LE29 (The following reaction is carried out in an N<sub>2</sub> atmosphere.) Dissolve Tetrakis-(triphenylphosphine)-palladium(0) (510mg, 0.45 mmol) and ester (46) (1.97g, 8.91mmol) in DME (16mL), degas the reaction mixture carefully (5 times) and flush with N<sub>2</sub>. Add 2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (2.15g, 9.80mmol) and a 1 M aqueous NaHCO<sub>3</sub> solution (27.0mL, 27.0mmol), degas the reaction mixture again carefully (5 times) and flush with N<sub>2</sub>. Stir the mixture for 18h at 95°C. Partition the

reaction solution between EtOAc and water and extract the separated aqueous layer with EtOAc (3 times). Wash combined organic layer with brine and dry it with Na<sub>2</sub>SO<sub>4</sub>. Purify the crude product by flash chromatography (silica gel, CyH/EtOAc 5+1] to obtain 5-(2-Amino-phenyl)-thiophene-2-carboxylic acid methyl ester (47) as a yellow solid (1.41g, 67%).  
 5 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.88 (s, 3 H); 4.00 (s, 2 H); 6.73-6.82 (m, 2 H); 7.13-7.21 (m, 2 H); 7.26 (dd, 1 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.0 Hz); 7.78 (d, 1 H, *J* = 3.8 Hz).

### 2',4',6'-Trimethoxy-biphenyl-3-carbonyl chloride (51)

SCHEME 9



**Step 1:** KM03 Dissolve 1,3,5-trimethoxybenzene (10.0 g, 59.46 mmol) in anhydrous dichloromethane (100 mL), cool the reaction mixture to -78°C, add dropwise bromine (3.0mL, 59.44 mmol) stir the mixture for 1h between -70°C and -40°C. Warm up the solution to 0°C and add water. Separate layers and extract the aqu. layer with EtAOc (3 times). Wash combined organic layer with water and brine and dry it with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent and purify the crude product by recrystallization from hot EtOAc and cyclohexane to obtain 2-Bromo-1,3,5-trimethoxy-benzene (48) as a white solid (8.84 g, 60%).  
 15 <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.80 (s, 3 H); 3.86 (s, 6 H); 6.15 (s, 2 H).


**Step 2:** FR542 (The following reaction is carried out in a N<sub>2</sub> atmosphere.) Dissolve Pd(PPh<sub>3</sub>)<sub>4</sub> (342mg, 0.30mmol) and 2-Bromo-1,3,5-trimethoxy-benzene (48) (2.44g, 9.87mmol) in DME (20mL) and stir for 15min at rt. Add 3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid ethyl ester (3.16g, 11.45mmol) followed by an aqu.



1M sodium bicarbonate solution (29.6mL, 29.6mmol). Degas the reaction mixture carefully, flush with N<sub>2</sub> (5 times) and stir for 20h at 100°C (reflux). Cool reaction mixture to rt, remove organic solvent under reduced pressure and partition the residue between water and EtOAc. Extract the aqu. layer with EtOAc (3 times), wash the combined organic layer with water and brine and dry it with Na<sub>2</sub>SO<sub>4</sub>. Purify the obtained crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+3) to obtain the biphenyl (49) (2.41g, 77%) as a brown oil. <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 1.35 (t, 3 H, *J* = 7.1Hz); 3.70 (s, 6 H); 3.85 (s, 3 H); 4.35 (q, 2 H, *J* = 7.8Hz); 6.21 (s, 2 H); 7.42 (t, 1 H, *J* = 7.6Hz); 7.95 (br.d, 1 H, *J* = 7.8Hz); 7.99 (br.s, 1 H).

10     **Step 3:** FR543 Dissolve the biphenyl (49) (2.41g, 7.62mmol) in MeCN (76mL) and add 1M aqu LiOH (38.0mL, 38.0mmol). Stir reaction mixture for 4h under reflux. Quench the cooled reaction mixture (cooling bath) with 1M aqu. HCl (to get pH ca. 3). Extract the mixture with EtOAc (3x), wash the combined organic layer with water and brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent and dry the residue without further purification in oil pump vacuum to obtain carboxylic acid (50) as a yellow solid (2.25g, quant.). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.71 (s, 6 H); 3.85 (s, 3 H); 6.21 (s, 2 H); 7.45 (t, 1 H, *J* = 7.7 Hz); 7.56 (br.d, 1 H, *J* = 7.8 Hz); 8.00 (br.d, 1 H, *J* = 7.6 Hz); 8.06 (br. s, 1 H).


20     **Step 4:** DU011 (The following reaction is carried out in an anhydrous N<sub>2</sub> atmosphere.) Dissolve carboxylic acid (50) (1.00g, 3.50mmol) in anhydrous dichloromethane (23mL) and add anhydrous DMF (5 drops). Add slowly oxalyl chloride (460μL, 5.25mmol) by keeping temperature at ca. 20°C with a water bath and stir for additional 2h at rt. Remove solvent and dry the residue in vacuum to obtain crude 2',4',6'-Trimethoxy-biphenyl-3-carbonyl chloride (51) (1.10g, quant.) as a yellow solid. No further purification.

**5-(4-Amino-phenyl)-2-methyl-furan-3-carboxylic acid methyl ester (54)****SCHEME 10**


5

**Step 1:** DK001(The following reaction is carried out under exclusion of light.) Dissolve 2-Methyl-furan-3-carboxylic acid methyl ester (52) (3.60mL, 28.5mmol) in chloroform (20mL) and glacial acetic acid (20mL) and add NBS (6.90g, 38.8mmol) portionwise in between a period of 95min. Stir the reaction suspension for additional 19h at rt. Add water to the reaction mixture and extract the aqu. layer with dichloromethane (2 times), wash the combined organic layer with 2M aqu. NaOH, water (3 times) and brine and dry it with  $\text{Na}_2\text{SO}_4$  to obtain 5-Bromo-2-methyl-furan-3-carboxylic acid methyl ester (53) (4.90g, 78%) as a red brown oil. No further purification.  $^1\text{H}$  NMR (400MHz,  $\text{CDCl}_3$ ): 2.54 (s, 3 H); 3.80 (s, 3 H); 6.53 (s, 1 H).

**Step 2:** DK002+003 (The following reaction is carried out in a  $\text{N}_2$  atmosphere.) Dissolve  $\text{Pd(PPh}_3)_4$  (1.26g, 1.09mmol) and 5-Bromo-2-methyl-furan-3-carboxylic acid methyl ester (53) (4.77g, 21.77mmol) in DME (116mL) and stir for 15min at rt. Add 4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (5.25g, 23.96mmol) followed by an aqu. 1M sodium bicarbonate solution (65.4mL, 65.3mmol). Degas the reaction mixture carefully, flush with  $\text{N}_2$  (5 times) and stir for 4h at  $95^\circ\text{C}$  (reflux). Cool reaction mixture to rt, remove organic solvent under reduced pressure and partition the residue between water and EtOAc. Extract the aqu. layer with EtOAc (3 times), wash the combined organic layer with water and brine and dry it with  $\text{Na}_2\text{SO}_4$ . Purify the obtained crude product by flash chromatography (silica gel, EtOAc/CyH 1+2) to obtain 5-(4-Amino-phenyl)-2-methyl-furan-3-carboxylic acid methyl ester (54) (2.35g, 46%) as a yellow-brown solid.  $^1\text{H}$  NMR (400MHz,  $\text{CDCl}_3$ ): 2.60 (s, 3 H); 3.74 (br.s, 2 H); 3.82 (s, 3 H); 6.64 (s, 1 H); 6.67 (dt, 1 H,  $J_1 = 8.6\text{Hz}$ ,  $J_2 = 2.3\text{Hz}$ ); 7.42 (dt, 2 H,  $J_1 = 8.8\text{Hz}$ ,  $J_2 = 2.3\text{Hz}$ ).

**2-Thiophen-2-yl- phenylamine (55)****SCHEME 11**

**Step 1:** AB427 (The following reaction is carried out in an  $\text{N}_2$  atmosphere.) Dissolve Tetrakis-(triphenylphosphine)-palladium(0) (297mg, 0.26 mmol) and 2-Bromo-thiophene (837mg, 5.13mmol) in DME (42mL), degas the reaction mixture carefully (5 times) and flush with  $\text{N}_2$ . After 10min stirring add 2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (1.24g, 5.64mmol) and a 1M aqueous  $\text{NaHCO}_3$  solution (15.4mL, 15.4mmol), degas the reaction mixture again carefully (5 times) and flush with  $\text{N}_2$ . Stir the mixture for 3h at  $95^\circ\text{C}$ . Cool mixture to rt, remove solvent under reduced pressure and partition the residue between EtOAc and water. Extract the separated aqueous layer with EtOAc (3 times). Wash combined organic layer with brine and dry it with  $\text{Na}_2\text{SO}_4$ . Purify the crude product by flash chromatography (silica gel 60, CyH/EtOAc 15+1] to obtain 2-Thiophene-2-yl-phenylamine (55) as a brown solid (825mg, 92%).  $^1\text{H}$  NMR (400MHz,  $\text{CDCl}_3$ ): 4.40-6.00 (m, 2 H); 6.88 (td, 1 H,  $J_1 = 7.6$  Hz,  $J_2 = 1.0$  Hz); 6.93 (dd, 1 H,  $J_1 = 8.0$  Hz,  $J_2 = 1.0$  Hz); 7.07 (dd, 1 H,  $J_1 = 5.3$  Hz,  $J_2 = 3.5$  Hz); 7.17 (td, 1 H,  $J_1 = 8.0$  Hz,  $J_2 = 1.5$  Hz) 7.22 (dd, 1 H,  $J_1 = 3.5$  Hz,  $J_2 = 1.3$  Hz); 7.30 (dd, 1 H,  $J_1 = 7.6$  Hz,  $J_2 = 1.5$  Hz); 7.33 (dd, 1 H,  $J_1 = 5.3$  Hz,  $J_2 = 1.3$  Hz).

**[5-(3-Amino-phenyl)-thiophen-2-yl]-acetic acid methyl ester (57)****SCHEME 12**

**Step 1:** FR544 (The following reaction is carried out in an  $\text{N}_2$  atmosphere.) Dissolve Tetrakis-(triphenylphosphine)-palladium(0) (1.12g, 0.97 mmol) and ester (43) (4.57g, 19.44mmol) in toluene (200mL) and EtOH (20.0mL), degas the reaction mixture carefully (5 times) and flush with  $\text{N}_2$ . Add 3-nitrophenylboronic acid (3.57g, 21.38mmol) and a 3 M aqueous  $\text{Na}_2\text{CO}_3$  solution (18.1mL, 54.3mmol), degas the reaction mixture again carefully (5 times) and flush with  $\text{N}_2$ . Stir the mixture for 18h at  $100^\circ\text{C}$ . Partition the reaction solution between EtOAc and water and extract the separated aqueous layer with EtOAc (3 times). Wash combined organic layer with brine and dry it with  $\text{Na}_2\text{SO}_4$ . Purify the obtained crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+5) to obtain [5-(3-nitro-phenyl)-thiophen-2-yl]-acetic acid methyl ester (56) as a yellow solid (3.15g, 58%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ): 3.75 (s, 3 H); 3.85 (s, 2 H); 6.94 (br.d, 1 H,  $J = 3.8$  Hz); 7.27 (d, 1 H,  $J = 3.8$  Hz); 7.51 (t, 1 H,  $J = 8.0$  Hz); 7.84 (ddd, 1 H,  $J_1 = 7.8$  Hz,  $J_2 = 1.5$  Hz,  $J_3 = 0.8$  Hz); 8.08 (ddd, 1 H,  $J_1 = 8.3$  Hz,  $J_2 = 2.1$  Hz,  $J_3 = 1.0$  Hz); 8.39 (t, 1 H,  $J = 1.9$  Hz).


**Step 2:** (The following reaction is done in an  $\text{N}_2$  atmosphere.) Dissolve [5-(3-Nitro-phenyl)-thiophen-2-yl]-acetic acid methyl ester (56) (3.15mg, 11.35mmol) in MeOH (225mL) and add Pd on carbon (10% (w/w) Pd content, 1.20g, 1.13mmol) followed by  $\text{NH}_4\text{CO}_2\text{H}$  (7.15g, 113.4mmol) at rt. Degas the reaction mixture carefully (flush with  $\text{N}_2$ ) and stir it for 22h at rt. Filtrate reaction mixture through a short pad of celite and remove solvent. Purify the obtained crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+3) to obtain [5-(3-Amino-phenyl)-thiophen-2-yl]-acetic acid methyl ester

(57) (2.08g, 74%) as a yellow solid.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ): 3.73 (s, 3 H); 3.81 (s, 2 H); 6.59 (dd, 1 H,  $J_1 = 7.8$  Hz,  $J_2 = 2.0$  Hz); 6.86 (br.d, 1 H,  $J = 3.5$  Hz); 6.88 (t, 1 H,  $J = 1.9$  Hz); 6.97 (br.d, 1 H,  $J = 7.6$  Hz); 7.09 (d, 1 H,  $J = 3.5$  Hz); 7.13 (t, 1 H,  $J = 7.7$  Hz).

### 5 EXAMPLE 3

2-Methyl-5-{4-[(2',4',6'-trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-furan-3-carboxylic acid (60) REV968

**SCHEME 13**



10

**Step 1: AB438** (The following reaction is done in an anhydrous  $\text{N}_2$  atmosphere.)

Dissolve the aniline (54) (150mg, 0.65mmol) in anhydrous dichloromethane (10.0mL), add  
 15 anhydrous pyridine (1.7mL) and the carboxylic acid chloride (51) (218mg, 0.71mmol). Stir  
 the reaction mixture for 20h at rt. Pour the reaction mixture into ice cooled 1M aq. HCl,  
 extract with EtOAc (3x), wash the combined organic layer with water and brine and dry

with Na<sub>2</sub>SO<sub>4</sub>. Purify the obtained crude product by preparative radial chromatography (silica gel, EtOAc/CyH 1+5, later 1+3, later 1+1) to obtain the amide (58) as a yellow solid (95mg, 29%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 2.63 (s, 3 H); 3.72 (s, 6 H); 3.83 (s, 3 H); 3.86 (s, 3 H); 6.23 (s, 2 H); 6.81 (s, 1 H); 7.46-7.53 (m, 2 H); 7.61 (d, 2 H, *J* = 8.5 Hz); 7.66 (d, 2 H, *J* = 8.6 Hz); 7.76-7.82 (m, 3 H).

**Step 2: AB439** Dissolve the ester (58) (71mg, 0.14mmol) in THF (2.4mL) and MeOH (0.6mL) and add 1M aqu LiOH (710μL, 0.71mmol). Stir the reaction mixture for 24h at rt. Remove solvent under reduced pressure und partition residue between EtOAc and 1 M HCl . Separate the aqueous layer and extract 3 times with EtOAc. Wash the combined organic layer with water and brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain crude product (59) as a beige solid (68mg, 99%). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>): 2.59 (s, 3 H); 3.67 (s, 6 H); 3.83 (s, 3 H); 6.34 (s, 2 H); 6.99 (s, 1 H); 7.38 (br.d, 1 H, *J* = 7.6 Hz); 7.48 (t, 1 H, 7.7 Hz); 7.67 (d, 2 H, *J* = 8.8 Hz); 7.77 (br.s, 1 H); 7.81-7.87 (m, 3 H); 10.29 (s, 1 H); 12.60 (br.s, 1 H).

**Step 3: AB440** (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.)


Suspend carboxylic acid (59) (65mg, 0.13mmol) in anhydrous dichloromethane (2.7mL) and anhydrous 1,2-dichloroethane (2.0mL), cool the solution to -78°C and add dropwise a 1M solution of BBr<sub>3</sub> in dichloromethane (800μL, 0.80mmol). Stir the reaction mixture for 10min at -78°C and after slowly warming up for additional 4h at rt. Cool reaction mixture to 0°C, add dropwise water and dichloromethane followed by EtOAc. Separate the aqueous layer and extract 3 times with EtOAc. Wash the combined organic layer with brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and purify crude product by preparative RP HPLC (gradient, water/CH<sub>3</sub>CN 95:5 to 5:95) to obtain 2-Methyl-5-{4-[(2',4',6'-trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-furan-3-carboxylic acid (60) (11mg, 19%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): 2.68 (s, 3 H); 6.03 (s, 2 H); 6.95 (s, 1 H); 7.52 (t, 1 H, *J* = 7.7 Hz); 7.61 (dt, 1 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.3 Hz) 7.71 (d, 2 H, *J* = 8.8 Hz); 7.81 (d, 2 H, *J* = 8.8 Hz); 7.83 (dt, 1 H, *J*<sub>1</sub> = 8.1 Hz, *J*<sub>2</sub> = 1.4 Hz), 7.95 (t, 1 H, *J* = 1.5 Hz).

## EXAMPLE 4

(5-{2-[(2',4',6'-Trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid (63) REV974

5

## SCHEME 14



**Step 1:** FR600 (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.)

- 10 Dissolve the aniline (44) (823mg, 3.33mmol) in anhydrous dichloromethane (17.0mL), add anhydrous pyridine (680μL, 8.33mmol) and the carboxylic acid chloride (51) (1.67g, 4.32mmol). Stir the reaction mixture for 20h at rt. Pour the reaction mixture into ice cooled 1M aq. HCl, extract with EtOAc (3x), wash the combined organic layer with brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Purify crude product by preparative radial chromatography (silica gel
- 15 60PF, CyH/EtOAc 3+1) to obtain the amide (61) as a yellow solid (722mg, 41%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 3.69 (s, 6 H); 3.72 (s, 3 H); 3.80 (s, 2 H); 3.86 (s, 3 H); 6.21 (s, 2 H); 6.92 (d, 1 H, *J* = 3.5 Hz); 7.01 (d, 1 H, *J* = 3.5 Hz); 7.14 (t, 1 H, *J* = 7.3 Hz); 7.36-7.42 (m, 2 H); 7.44 (d, 1 H, *J* = 7.8 Hz); 7.48 (br.d, 1 H, *J* = 7.6 Hz); 7.61 (br.d, 1 H, 7.3 Hz); 7.78 (br.s, 1 H); 8.35 (br.s, 1 H); 8.50 (d, 1 H, *J* = 8.3 Hz).

**Step 2: FR601** Dissolve the ester (61) (722mg, 1.39mmol) in MeCN (14.0mL) and add 1M aqu LiOH (7.0mL, 7.00mmol). Stir the reaction mixture for 20h at rt. Remove solvent under reduced pressure and partition residue between EtOAc and 1 M HCl (1+1). Separate the aqueous layer and extract 3 times with EtOAc. Wash the combined organic layer with  
5 brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain crude product (62) as a yellow solid (714mg, quant.). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN): 3.69 (s, 6 H); 3.80 (s, 2 H); 3.85 (s, 3 H); 6.30 (s, 2 H); 6.92 (d, 1 H, *J* = 3.5 Hz); 7.14 (d, 1 H, *J* = 3.8 Hz); 7.28 (td, 1 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.3 Hz); 7.39 (td, 1 H, *J*<sub>1</sub> = 7.8 Hz, *J*<sub>2</sub> = 1.3 Hz); 7.42-7.49 (m, 2 H); 7.54  
10 (dd, 1 H, *J*<sub>1</sub> = 7.8 Hz, *J*<sub>2</sub> = 1.3 Hz); 7.69 (br.s, 1 H); 7.73 (dt, 1 H, *J*<sub>1</sub> = 7.3 Hz, *J*<sub>2</sub> = 1.8 Hz); 7.89 (d, 1 H, *J* = 7.6 Hz); 8.53 (br. s, 1 H).


**Step 3: FR602** (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve carboxylic acid (62) (700mg, 1.39mmol) in anhydrous dichloromethane (28.0mL), cool the solution to -78°C and add dropwise a 1M solution of BBr<sub>3</sub> in dichloromethane (8.5mL,  
15 8.50mmol). Stir the reaction mixture for 10min at -78°C and after slowly warming up for additional 4h at rt. Cool reaction mixture to 0°C, add dropwise water and dichloromethane followed by EtOAc. Separate the aqueous layer and extract 3 times with EtOAc. Wash the combined organic layer with brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and purify crude product by preparative RP HPLC (gradient, water/CH<sub>3</sub>CN 95:5  
20 to 5:95) to obtain (5-{2-[(2',4',6'-Trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid (63) (146mg, 22%) as a beige solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) 3.85 (s, 2 H); 6.02 (s, 2 H); 6.97 (d, 1 H, *J* = 3.5 Hz); 7.18 (d, 1 H, *J* = 3.5 Hz); 7.35 (td, 1 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.3 Hz); 7.42 (td, 1 H, *J*<sub>1</sub> = 7.6 Hz, *J*<sub>2</sub> = 1.5 Hz); 7.50 (t, 1 H, *J* = 7.7 Hz); 7.61 (br.d, 2 H, *J* = 7.6 Hz); 7.79 (br.d, 2 H, *J* = 7.6 Hz); 7.93 (br.s, 1 H).



## EXAMPLE 5

(5-{2-[2-(2,4,6-Trihydroxy-phenyl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid (25)  
REV989, DU27

SCHEME 15



5

(5-{2-[2-(2,4,6-Trihydroxy-phenyl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid (25) is made starting from the amine (44) and carboxylic acid chloride (14) according to the procedure described in steps 1 to 3 of EXAMPLE 1 to obtain (5-{2-[2-(2,4,6-Trihydroxy-phenyl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid (25) (25mg, 16% over 3 steps) as a brown solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): 3.58 (s, 2 H); 3.88 (s, 2 H); 5.88 (s, 2 H); 6.67 (d, 1 H, *J* = 3.3 Hz); 6.84 (d, 1 H, *J* = 3.3 Hz); 7.14 (t, 1 H, *J* = 7.3 Hz); 7.31-7.37 (m, 2 H); 8.26 (d, 1 H, *J* = 8.6 Hz).


10

## EXAMPLE 6

5-{2-[(2',4',6'-trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophene-2-carboxylic acid (26) REV971, LE37

15

SCHEME 16




5- $\{2-[(2',4',6'-\text{trihydroxy-biphenyl-3-carbonyl})\text{-amino}]\text{-phenyl}\}$ -thiophene-2-carboxylic acid (26) is made starting from amine (47) and carboxylic acid chloride (51) according to the procedure described above in steps 1 to 3 of EXAMPLE 4 to obtain 5- $\{2-[(2',4',6'-$   
 5 trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophene-2-carboxylic acid (26) (44mg, 22% over 3 steps) as a white solid.  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ): 6.02 (s, 2 H); 7.32-7.36 (m, 1 H); 7.41 (t, 1 H,  $J = 7.6$  Hz); 7.46-7.53 (m, 2 H); 7.62 (dt, 1 H,  $J_1 = 7.6$  Hz,  $J_2 = 1.3$  Hz); 7.65-7.73 (m, 3 H); 7.80 (dt, 1 H,  $J_1 = 8.1$  Hz,  $J_2 = 1.4$  Hz); 7.96 (br.s, 1 H).

## 10 EXAMPLE 7

(5- $\{3-[(2',4',6'-\text{trihydroxy-biphenyl-3-carbonyl})\text{-amino}]\text{-phenyl}\}$ -thiophen-2-yl)-acetic acid (64) REV996, KM7

**SCHEME 17**



15

(5- $\{3-[(2',4',6'-\text{trihydroxy-biphenyl-3-carbonyl})\text{-amino}]\text{-phenyl}\}$ -thiophen-2-yl)-acetic acid (64) is made starting from amine (57) and carboxylic acid chloride (51) according to the procedure described above in steps 1 to 3 of EXAMPLE 4 to obtain (5- $\{3-[(2',4',6'-$   
 20 trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid (64) (3mg, 4% over 3 steps) as a brown solid.  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ): 3.88 (s, 2 H); 6.03 (s, 2 H); 6.97 (d, 1 H,  $J = 3.5$  Hz); 7.29 (d, 1 H,  $J = 3.8$  Hz); 7.36-7.44 (m, 2 H) 7.53 (t, 1 H,  $J = 7.7$  Hz); 7.61 (dt, 1 H,  $J_1 = 7.6$  Hz,  $J_2 = 1.4$  Hz); 7.66 (dt, 1 H,  $J_1 = 7.3$  Hz,


$J_2 = 1.8$  Hz), 7.85 (dt, 1 H,  $J_1 = 7.8$  Hz,  $J_2 = 1.5$  Hz); 7.96 (t, 1 H,  $J = 1.5$  Hz); 8.05 (br.s, 1 H).

## EXAMPLE 8

5

2',4',6'-Trihydroxy-biphenyl-3-carboxylic acid (2-thiophen-2-yl-phenyl)-amide (65)  
REV965, AB437

**SCHEME 18**



10

2',4',6'-Trihydroxy-biphenyl-3-carboxylic acid (2-thiophen-2-yl-phenyl)-amide (65) is made starting from amine (55) and carboxylic acid chloride (51) according to the procedure described above in steps 1 and 3 of EXAMPLE 4 to obtain 2',4',6'-Trihydroxy-biphenyl-3-carboxylic acid (2-thiophen-2-yl-phenyl)-amide (65) (12mg, 9% over 2 steps) as a beige solid.  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ): 6.02 (s, 2 H); 7.13 (dd, 1 H,  $J_1 = 5.1$  Hz,  $J_2 = 3.8$  Hz); 7.35 (dd, 1 H,  $J_1 = 3.5$  Hz,  $J_2 = 1.0$  Hz); 7.38 (dd, 1 H,  $J_1 = 7.6$  Hz,  $J_2 = 1.3$  Hz); 7.41-7.48 (m, 2 H); 7.50 (d, 1 H,  $J = 7.6$  Hz); 7.61 (dt, 1 H,  $J_1 = 7.8$  Hz,  $J_2 = 1.4$  Hz); 7.64 (dd, 1 H,  $J_1 = 7.6$  Hz,  $J_2 = 1.5$  Hz); 7.73 (dd, 1 H,  $J_1 = 7.8$  Hz,  $J_2 = 1.3$  Hz); 7.77 (dt, 1 H,  $J_1 = 8.1$  Hz,  $J_2 = 1.4$  Hz); 7.92 (t, 1 H,  $J = 1.5$  Hz).


20

## EXAMPLE 9

2',4',6'-Trihydroxy-biphenyl-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide (66)  
REV961, DU15

25

## SCHEME 19



2',4',6'-Trihydroxy-biphenyl-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide (66) is made starting from 3-trifluoromethyl-phenylamine and carboxylic acid chloride (51)


5 according to the procedure described above in steps 1 and 3 of EXAMPLE 4 to obtain 2',4',6'-Trihydroxy-biphenyl-3-carboxylic acid (3-trifluoromethyl-phenyl)-amide (66) (54mg, 54% over 2 steps) as a beige solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): 6.02 (s, 2 H); 7.45 (br.d, 1 H, *J* = 7.6 Hz); 7.53 (t, 1 H, *J* = 7.7 Hz); 7.58 (t, 1 H, *J* = 8.0 Hz); 7.62 (dt, 1 H, *J*<sub>1</sub> = 7.8 Hz, *J*<sub>2</sub> = 1.4 Hz); 7.85 (ddd, 1 H, *J*<sub>1</sub> = 7.8 Hz, *J*<sub>2</sub> = 1.8 Hz, *J*<sub>3</sub> = 1.3 Hz); 7.95-  
10 7.99 (m, 2 H); 8.21 (br.s, 1 H).

## EXAMPLE 10

3-[(2',4',6'-Trihydroxy-biphenyl-3-carbonyl)-amino]-benzoic acid (67) REV1007, LE80

15

## SCHEME 20




3-[(2',4',6'-Trihydroxy-biphenyl-3-carbonyl)-amino]-benzoic acid (67) is made starting from 3-Amino-benzoic acid methyl ester and carboxylic acid chloride (51) according to the  
20 procedure described above in steps 1 to 3 of EXAMPLE 3 to obtain 3-[(2',4',6'-Trihydroxy-biphenyl-3-carbonyl)-amino]-benzoic acid (67) (22mg, 14% over 3 steps) as

an off white solid.  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ ): 6.02 (s, 2 H); 7.48 (t, 1 H,  $J = 8.0$  Hz); 7.52 (t, 1 H,  $J = 7.8$  Hz); 7.61 (br.d, 1 H,  $J = 7.8$  Hz); 7.84 (t, 2 H,  $J = 7.2$  Hz); 7.96 (br.s, 1 H); 8.01 (br.d, 1 H,  $J = 8.3$  Hz); 8.34 (br.s, 1 H).

- 5 The compounds referred to in the following SCHEME 6 are those compounds referred to as the particularly preferred compounds herein.

SCHEME 6



**Sialyl Lewis<sup>x</sup> Tyrosine Sulfate Assay (sLe<sup>x</sup> TSA):**

Compounds of the present invention are assayed on a molecular level for their ability to inhibit the binding of P-, L-, or E-selectin chimeric molecules to sLe<sup>x</sup> and tyrosinesulfate residues linked to a polymeric matrix as a PSGL-1 substitute. Selected IC<sub>50</sub>-values are determined.

Microtiter plates are coated overnight in carbonate buffer pH9,6 with goat anti human Fc mAB (10 µg/ml). After washing in assay buffer (25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150mM NaCl, 1mM CaCl<sub>2</sub> pH7,4) and blocking (3% bovine serum albumin (BSA) in assay buffer) plates are incubated for 2h at 37°C with human P-Selectin-IgG-chimera (0,61nM respectively 150ng/mL) or human L-Selectin-IgG-chimera (0,61nM respectively 89ng/mL) or human E-Selectin-IgG-chimera (0,61nM respectively 131ng/mL). 5µl of sLe<sup>x</sup>-tyrosine sulfate polyacrylamide (1mg/ml) carrying 15% sLe<sup>x</sup>, 10% Tyrosine-sulfate and 5% biotin is complexed with 20µl Streptavidin-Peroxidase solution (1mg/ml) and 25µl assay buffer without CaCl<sub>2</sub>. For use in the assay, the ligand complex is diluted 1:10000 in assay buffer and further diluted 1:1 with varying amounts of compounds in assay buffer incl. 2%DMSO. This mixture is added to the wells precoated with E- or P-selectin. After incubation for 2h at 37°C, wells are washed for six times with in assay buffer incl. 0,005% Polyoxyethylenesorbitan monolaurate (TWEEN 20), developed for 10-15min with 20µl 3,3',5,5'-tetramethylbenzidine (TMB)/H<sub>2</sub>O<sub>2</sub> substrate solution and stopped with 20µl 1M H<sub>2</sub>SO<sub>4</sub>. Bound sLe<sup>x</sup>-Tyrosine sulfate ligand complex is determined by measuring optical density at 450nm vs. 620nm in a Fusion alpha-FP reader (sold from Packard Bioscience, Dreieich, Germany).

**Results from sLe<sup>x</sup>TSA: IC<sub>50</sub> Data for E-/ P-/ L-Selectin**

Compound	IC <sub>50</sub> E-Selectin [µM]	IC <sub>50</sub> P-Selectin [µM]	IC <sub>50</sub> L-Selectin [µM]
Bimosiamose	>500	95.0	>500
18	41.2	37.1	35.1
19	12.4	20.7	22.1

**Results from sLe<sup>x</sup>TSA: IC<sub>50</sub> Data for E-/ P-/ L-Selectin**

Compound	IC <sub>50</sub> E-Selectin [μM]	IC <sub>50</sub> P-Selectin [μM]	IC <sub>50</sub> L-Selectin [μM]
25	105.4	87.9	95.9
26	33.3	27.8	28.2
60	7.8	5.2	6.1
63	21.9	17.4	17.4
64	5.7	6.0	6.3
65	28.1	8.2	15.5
67	27.3	23.3	25.2

**Flow Chamber Assay / Cell Adhesion and Rolling under Flow Conditions**

- 5 To assess the capability of compounds to inhibit cell binding under dynamic conditions resembling the flow in a blood vessel, flow chamber assays addressing/ testing binding of HL-60 cells / various cell lines to P-selectin, L-selectin and E-selectin chimeric molecules are performed.

Cell attachment under flow conditions are determined using a parallel flow chamber  
 10 system. A 35mm polystyrene culture dish is coated for 1 hour at room temperature with coating buffer (50mM tris-(hydroxymethyl) aminomethane buffer (Tris), 150 mM NaCl, 2 mM CaCl<sub>2</sub>; pH 7,4) containing human E- or P-selectin-IgG chimera at concentrations of 2,5μg/ml or 10μg/ml, respectively. After removal of the coating solution non specific binding sites are blocked for an additional hour with 1% BSA in coating buffer at room  
 15 temperature. After washing with assay buffer ("Roswell Park Memorial Institute 1640" (RPMI 1640) + 10mM HEPES) the dish is fitted into a parallel plate laminar flow chamber (sold from Glycotech, Rockville, MD) and mounted on an inverted phase-contrast microscope (sold from Olympus, Hamburg, Germany) equipped with a CCD camera (JVC) that is connected to a PC. Employing a peristaltic pump (sold from Ismatec, Wertheim-  
 20 Mondfeld, Germany) the re-circulating system is equilibrated with assay buffer containing



125 $\mu$ M compound or vehicle control (DMSO). Cells (1 million / ml) are added to the chamber and allowed to distribute for 2 minutes at a high flow rate. The flow rate is then decreased resulting in a calculated flow shear of 1 dyne/cm<sup>2</sup>. Video sequences of 10 low power fields are digitally recorded after 5 minutes continuous flow. The percentage of inhibition is calculated from the mean number of cells per field that attached to the coated dish surface in the presence versus absence of compound of at independent experiments.

#### **Data from Flow Chamber Assay for E- and P-Selectin**

Values are given as normalized ratios of %-inhibition of compound x divided by %-inhibition of bimosiamose.


Compound	E-Selectin [Ratio]	P-Selectin [Ratio]
18	0.80	1.07
19	0.75	1.27

Compound	E-Selectin [Ratio]	P-Selectin [Ratio]
25	0.94	1.65
26	1.11	0.77
60	1.05	0.99
63	1.23	0.87
64	1.06	1.23
65	1.13	0.99
66	1.47	1.19
67	0.79	0.95

# Claims

1. Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine,


5



wherein the symbols and substituents have the following meaning

-X- =


(a)



10


with  $m = 0, 1$ ;  $n =$  an integer from 1 to 3

(b)




15

wherein "ring" is



and with  $R^1$  being H,  $\text{NO}_2$ ,  $\text{CF}_3$ , F, Cl, Br, I, CN,  $\text{CH}_3$ ,  $\text{NH}_2$ ,  $\text{NHAlkyl}$ ,  $\text{NHAr}$ ,  $\text{NHAcyl}$  and  $k = 0,1$


(c)



T being O, S or [H,H];  $p = 0,1,2$ ,

-Y =

(a)



with  $s$  being 0 or 1,

$R^2$  being  $\text{CO}_2\text{H}$ ,  $\text{CO}_2\text{Alkyl}$ ,  $\text{CO}_2\text{Aryl}$ ,  $\text{CO}_2\text{NH}_2$ ,  $\text{CO}_2\text{Aralkyl}$ ,  $\text{SO}_3\text{H}$ ,  $\text{SO}_2\text{NH}_2$ ,  $\text{PO}(\text{OH})_2$ , 1-H-tetrazolyl-,  $\text{CHO}$ ,  $\text{COCH}_3$ ,  $\text{CH}_2\text{OH}$ ,  $\text{NH}_2$ ,  $\text{NHAlkyl}$ ,  $\text{N}(\text{Alkyl})\text{Alkyl}$ ,  $\text{OCH}_3$ ,  $\text{CH}_2\text{OCH}_3$ ,  $\text{SH}$ , F, Cl, Br, I,  $\text{CH}_3$ ,  $\text{CH}_2\text{CH}_3$ , CN,  $\text{CF}_3$

$R^3$  independently from  $R^2$  being H,  $\text{CH}_3$ ,  $\text{CH}_2\text{CH}_3$ ,  $\text{CF}_3$ , F, Cl, Br, I, CN,  $\text{NO}_2$  and


$R^4$  independently from  $R^2$  and  $R^3$  being H,  $\text{CH}_3$ ,  $\text{CH}_2\text{CH}_3$ ,  $\text{CF}_3$ , F, Cl, Br, I, CN,  $\text{NO}_2$ ,  $R^2$

$R^5$  being H,  $\text{NO}_2$ ,  $\text{CF}_3$ , F, Cl, Br, I, CN,  $\text{CH}_3$ ,  $\text{OCH}_3$ ,  $\text{SH}$ ,  $\text{NH}_2$

and  $-\text{W}- = -(\text{CH}_2)_v$ , *cis*- $\text{CH}=\text{CH}-$  or *trans*- $\text{CH}=\text{CH}-$ , and  $v$  being 0,1,2;


in case that  $-\text{W}-$  is *cis*- $\text{CH}=\text{CH}-$  or *trans*- $\text{CH}=\text{CH}-$ ,  $R^2$  must not be  $\text{NH}_2$  or  $\text{SH}$ ;

(b)




$R^6$  independently from  $R^2$  being H, F, Cl, Me, tert-Bu, CN,  $NH_2$

(c)




(e)



with  $t$  being 0,1,2

$-Z =$

(i)




$R^7$  independently from  $R^2$  being H,  $NO_2$ ,  $CF_3$ , F, Cl, Br, I, CN,  $CH_3$ ,  $OCH_3$ , SH,  $NH_2$ ,

(iv)




with  $K = NH, NMe, O, S$

(v)




or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formula (I).

2. Pharmaceutical compositions according to claim 1, wherein the compounds are defined by formula (II)




wherein -X'- is X (a) or X (b) and -Y is as defined in claim 1.


3. Pharmaceutical compositions according to claim 2, wherein the compounds are defined by formulas (A) or (B)



wherein -X'- and -Y are as defined in claim 2 and wherein -X''- is



and wherein -Y' is




5

wherein all indices, symbols and substituents are as defined in claim 1.


4. Pharmaceutical compositions according to claim 3, wherein the compounds are defined by formula (C).

10




wherein -X''- and -Y' are as defined in claim 3.

5. Pharmaceutical compositions according to claim 4, wherein the compounds are defined by formula (D)



wherein -X''- is as defined in claim 3 and -Y'' is



with  $R^9$  being  $\text{CO}_2\text{H}$ ,  $\text{CO}_2\text{alkyl}$ ,  $\text{CO}_2\text{aryl}$ ,  $\text{CO}_2\text{NH}_2$ ,  $\text{CO}_2\text{aralkyl}$ ,  $\text{CH}_2\text{SO}_3\text{H}$ ,  $\text{CH}_2\text{SO}_2\text{NH}_2$ ,  $\text{CH}_2\text{PO}(\text{OH})_2$ , 1-H-tetrazolyl,  $\text{CHO}$ ,  $\text{COCH}_3$ ,  $\text{CH}_2\text{OH}$ ,  $\text{CH}_2\text{NH}_2$ ,  $\text{CH}_2\text{NHalkyl}$ ,  $\text{CH}_2\text{N(alkyl)alkyl'}$ ,  $\text{CH}_2\text{OCH}_3$ ,  $\text{CH}_2\text{SH}$ ,

wherein all indices, symbols and substituents are as defined in claim 1.

6. Chemical compounds having the general structure of formula (C) or (D) according to claim 4 or 5.

7. Use of compounds having the structure of formula (I) as defined in claim 1 for the preparation of a medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD), acute lung injury (ALI), cardiopulmonary bypass, acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis, chronic inflammatory diseases such as psoriasis, atopic dermatitis, and rheumatoid arthritis, and reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, and organ transplants, traumatic shock, multi-organ failure,

autoimmune diseases like multiple sclerosis, percutaneous transluminal angioplasty, asthma and inflammatory bowel disease.

- 5 8. Use of compounds having the structure of formula (I) as defined in claim 1 for the preparation of a medicine for the treatment, diagnosis or prophylaxis of inflammatory disorders.
9. Use of compounds having the structure of formula (I) as defined in claim 1 for the preparation of a vehicle for drug targeting of diagnostics or therapeutics.
- 10 10. Use of compounds having the structure of formulas (I) as defined in claim 1 for the preparation of a cosmetic or dermatological composition.
11. Cosmetic compositions comprising at least one compound of the formulas (I)  
15 as in claim 1 and at least one cosmetically tolerable component.
12. Dermatological compositions comprising at least one compound of formulas (I) as in claim 1 and at least one dermatologically tolerable component.



# INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/009153

## A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/167	A61K31/191	A61K31/341	A61K31/381	A61K31/4418
A61K31/4436	A61K31/505	A61K31/5377	C07D213/30	C07D213/40
C07D213/75	C07D239/20	C07D307/68	C07D333/24	C07D409/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, MEDLINE, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP 1 577 289 A (REVOTAR BIOPHARMACEUTICALS AG) 21 September 2005 (2005-09-21) abstract paragraph [0014] - paragraph [0021] * page 25, Scheme 11 * claims 1-7	1-12
A	US 6 248 790 B1 (UCKUN FATIH M ET AL) 19 June 2001 (2001-06-19) abstract column 1, line 35 - line 54 example 1 claims 1-23 ----- -/--	1-12

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

17 January 2007

Date of mailing of the international search report

26/01/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Taylor, Mark

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2006/009153

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 2003, no. 06, 3 June 2003 (2003-06-03) & JP 2003 055369 A (UNIV NIHON), 26 February 2003 (2003-02-26) abstract	1-12
A	WO 97/01335 A (TEXAS BIOTECHNOLOGY CORPORATION; KOGAN, TIMOTHY, P; DUPRE, BRIAN; SCOT) 16 January 1997 (1997-01-16) cited in the application abstract claims 1-9	1-12
A	EP 1 481 669 A (YAMANOUCHI PHARMACEUTICAL CO. LTD) 1 December 2004 (2004-12-01) cited in the application abstract claims 1-21	1-12
A	MANNISTO P T ET AL: "CATECHOL-O-METHYLTRANSFERASE (COMT): BIOCHEMISTRY, MOLECULAR BIOLOGY, PHARMACOLOGY, AND CLINICAL EFFICACY OF THE NEW SELECTIVE COMT INHIBITORS" PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 51, no. 4, 1999, pages 593-628, XP001203431 ISSN: 0031-6997 cited in the application the whole document	1-12
T	FRIEDRICH , M ET AL.: "Pan-selectin antagonism improves psoriasis manifestation in mice and man" ARCH DERMATOL RES, vol. 297, 2006, pages 345-351, XP002370636 the whole document	1-12
P,A	EP 1 627 644 A (HISAMITSU PHARMACEUTICAL CO [JP]) 22 February 2006 (2006-02-22) abstract claims 1-13	1-12

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2006/009153

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-12  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-12

Present claims 1-12 relate to an extremely large number of possible compounds/ compositions and their use in medicine. Support and disclosure in the sense of Art.

5 and 6 PCT is to be found however for only a very small proportion of the compounds/ compositions claimed (see page 28, Scheme 6, Examples 1 and 2).

The non-compliance with the substantive provisions is to such an extent that a meaningful search of the whole scope of the claims could not be carried out. The extent of the search was consequently limited.

The search of claims 1-12 was restricted to those compounds which appear to be supported and a generalisation of their structural formulae, namely those compounds represented on page 53, Scheme 6, as well as the compounds tested on pages 54-56, and their use in medicine and cosmetics.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2006/009153

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1577289	A	21-09-2005	WO 2005090284 A1	29-09-2005
US 6248790	B1	19-06-2001	US 2002010217 A1	24-01-2002
JP 2003055369	A	26-02-2003	NONE	
WO 9701335	A	16-01-1997	AT 193647 T	15-06-2000
			AU 704596 B2	29-04-1999
			AU 6292396 A	30-01-1997
			BR 9608873 A	06-07-1999
			CA 2221991 A1	16-01-1997
			CN 1196678 A	21-10-1998
			CZ 9704075 A3	15-07-1998
			DE 69608804 D1	13-07-2000
			DE 69608804 T2	02-11-2000
			DK 840606 T3	07-08-2000
			EP 0840606 A1	13-05-1998
			ES 2146886 T3	16-08-2000
			FI 974618 A	23-12-1997
			GR 3034289 T3	29-12-2000
			HU 9802602 A2	01-02-1999
			JP 11508885 T	03-08-1999
			NO 976074 A	02-03-1998
			PL 324330 A1	25-05-1998
			PT 840606 T	30-11-2000
			RU 2165931 C2	27-04-2001
EP 1481669	A	01-12-2004	NONE	
EP 1627644	A	22-02-2006	WO 2004112837 A1	29-12-2004
			US 2006188557 A1	24-08-2006